[ad_1]
The pre-purchase agreement stipulates that the future of the transaction will depend on a decision by the European Union pharmaceutical supervisory authority, the European Medicines Agency (EMA), on whether Novavax can be used to vaccinate against COVID-19, the EC said. . in a sentence.
If distribution is authorized, EU Member States will be able to purchase up to € 100 million. Novavax vaccine dose and another 100 million. additional doses. Community members will also be able to donate vaccines to low- and middle-income countries or offer them to other European countries.
The new anticipated agreement complements the already large basket of vaccines to be produced in Europe. To date, agreements have been signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, Moderna and preparatory negotiations with Valneva have been successfully completed.
This is another important step to ensure that Europe is well prepared to deal with the COVID-19 pandemic, the European Commission noted.
EC President Ursula von der Leyen said: “As new coronavirus strains spread in Europe and around the world, this new contract with a company that is already successfully testing its vaccine against these strains is a additional means to protect our population. It reinforces our large basket of vaccines, which benefits Europeans and our partners around the world ”.
Stella Kyriakides, European Commissioner for Health and Food Safety, said: the citizens.
The new agreement with Novavax expands our vaccine basket to include another protein vaccine that shows promise in clinical trials. We will continue to work tirelessly to ensure that our vaccines continue to reach citizens in Europe and around the world, so that the pandemic ends as soon as possible. “
Novavax is a biotechnology company that develops a new generation of vaccines against serious infectious diseases. The EMA is already conducting a review of its COVID-19 vaccine with a view to granting a marketing authorization.
The European Commission has decided to support this vaccine based on solid scientific data, the technology used, the company’s experience in vaccine development and its production capacity, which is sufficient to supply the entire EU.
In light of current and new immunologically unrecognized strains of SARS-CoV-2, the European Commission and Member States are also negotiating new contracts with companies whose vaccines are already in the EU vaccine basket to procure enough vaccines from emergency to boost immunity and extend.
The launch of the COVID-19 vaccination campaign in the EU-27 was slow earlier this year, but is now gaining momentum.
In the Community, 50.7% of the 445 million population, according to official national data summarized by the AFP news agency.
Unlike BioNTech / Pfizer, Moderna, and Curevac, which rely on the transfer of mRNA encoding the genetic information from viral proteins to human cells, the Novavax two-dose vaccine is based on a more traditional method. It contains harmless elements of the coronavirus that stimulate the body’s immune response.
However, this preparation does not need to be stored at extremely low temperatures and can therefore have a logistical advantage.
Maryland-based Novavax says the vaccine is 90 percent effective in protecting against severe forms of COVID-19, based on clinical trials in North America. Supervisory authorities in the US and the EU have yet to provide effectiveness evaluations.
